William WN, et al. - In this clinical study, the hypothesis that the addition of erlotinib to first-line cisplatin and docetaxel for patients with recurrent and/or metastatic head and neck squamous cell carcinomas (HNSCC) would yield a response rate of at least 50%, representing an improvement from historical controls, was tested. Improved response rates were achieved compared with historical controls.